
## Alessandra Cataldo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3297209/publications.pdf Version: 2024-02-01



ALESSANDRA CATALDO

#	Article	IF	CITATIONS
1	What if the future of HER2â€positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study. Cancer Medicine, 2022, 11, 332-339.	1.3	6
2	Breast Cancer Drug Resistance: Overcoming the Challenge by Capitalizing on MicroRNA and Tumor Microenvironment Interplay. Cancers, 2021, 13, 3691.	1.7	20
3	Macrophages Impair TLR9 Agonist Antitumor Activity through Interacting with the Anti-PD-1 Antibody Fc Domain. Cancers, 2021, 13, 4081.	1.7	5
4	miR-205 in Breast Cancer: State of the Art. International Journal of Molecular Sciences, 2021, 22, 27.	1.8	33
5	miR-9-Mediated Inhibition of EFEMP1 Contributes to the Acquisition of Pro-Tumoral Properties in Normal Fibroblasts. Cells, 2020, 9, 2143.	1.8	13
6	MiR-302b as a Combinatorial Therapeutic Approach to Improve Cisplatin Chemotherapy Efficacy in Human Triple-Negative Breast Cancer. Cancers, 2020, 12, 2261.	1.7	12
7	MicroRNA and Oxidative Stress Interplay in the Context of Breast Cancer Pathogenesis. International Journal of Molecular Sciences, 2019, 20, 5143.	1.8	30
8	MicroRNA co-expression patterns unravel the relevance of extra cellular matrix and immunity in breast cancer. Breast, 2018, 39, 46-52.	0.9	11
9	MicroRNAs and DNA-Damaging Drugs in Breast Cancer: Strength in Numbers. Frontiers in Oncology, 2018, 8, 352.	1.3	13
10	MiR-205 as predictive biomarker and adjuvant therapeutic tool in combination with trastuzumab. Oncotarget, 2018, 9, 27920-27928.	0.8	14
11	Exosome-mediated delivery of miR-9 induces cancer-associated fibroblast-like properties in human breast fibroblasts. Cell Death and Disease, 2016, 7, e2312-e2312.	2.7	232
12	miR-302b enhances breast cancer cell sensitivity to cisplatin by regulating E2F1 and the cellular DNA damage response. Oncotarget, 2016, 7, 786-797.	0.8	70
13	High efficacy of CpG-ODN, Cetuximab and Cisplatin combination for very advanced ovarian xenograft tumors. Journal of Translational Medicine, 2013, 11, 25.	1.8	18
14	Increased Sensitivity to Chemotherapy Induced by CpG-ODN Treatment Is Mediated by microRNA Modulation. PLoS ONE, 2013, 8, e58849.	1.1	21